In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
October 23rd, 2018
We describe an easy protocol specifically designed to reach precise and controlled concentrations of sevoflurane or isoflurane in vitro in order to improve our understanding of mechanisms involved in the epithelial lung injury and to test novel therapies for acute respiratory distress syndrome.
This method can help answer key question in the research field of lung injury and repair such as testing halogenated adjunct as potential novel therapies for acute respiratory distress syndrome. The main advantage of this technique is that it relies on a very simple method to culture the cells and to expose them to halogenated agents in order to reach precise and controlled concentrations. To construct the airtight chamber, use a hermetic polypropylene box with a capacity of 6.5 liters.
Drill a 2.5 centimeter diameter hole on the bottom side of the lateral wall of the box. Then insert a corrugated tube with a green mark which will serve as the gas air mixture input pipe. And seal it with silicone.
Next, drill a second hole with a 2.5 centimeter diameter on the top side of the opposite lateral wall. Insert another corrugated tube with a red mark and connect it with a charcoal filter which will serve as the gas air mixture output pipe. Then seal it with silicone.
Subsequently drill a tight hole with a four millimeter diameter at the center of the wall. Insert the short infusion tubing that is connected at a manifold with a rotating male lure lock. Plug it in to a gas analyzer and seal it with silicone.
Then place a digital thermometer inside the airtight chamber. Under a laboratory extractor hood, customize an anesthetic machine circuit to switch the nitrous oxide gas line by carbon dioxide. Insert a heated humidifier into the pipe between the anesthetic machine and the airtight chamber to warm the gas flow mixture to approximately 37 degrees Celsius.
Plug the airtight chamber with the green marked corrugated tube into the customized anesthetic machine circuit. Next, place the airtight chamber on a hot plate set to 37 degrees Celsius. Place a six well plate containing human alveolar epithelial cells into the airtight chamber and seal the lid.
Regulate the gas flow rate to quickly obtain 5%of CO2. Then open the halogenated agent evaporator and adjust the desired percentage. Once the target values are achieved, reduce the fresh gas flow rate to one liter per minute.
The airtight chamber can be maintained with this gas flow rate as long as necessary for the experiment. The courses of the sevoflurane and isoflurane concentrations in the medium were similar over time. Immediately after the required concentration of halogenated agent was set, concentrations rose over the first hour.
A plateau was then reached which persisted until the administration of the halogenated agent was stopped. After administration interruption, concentrations decreased within one hour. Shown here are the fractions of halogenated agent over time in the airtight chamber measured by the gas analyzer.
This procedure is relatively inexpensive and very easy to adopt even when researchers have never manipulated an airtight chamber before. Following this procedure, other methods like protein and RNA quantification, immunofluorescence, measurement of protein permeability and free transport can be performed in order to answer questions on the specific effects of the halogenated agents during epithelial lung injury and its resolution. After its development, this technique may pave the way for research in the field of acute respiratory distress syndrome to further study the mechanism involved in epithelial lung injury during ARDS and to test novel therapies.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a straightforward protocol for achieving precise concentrations of sevoflurane or isoflurane in vitro. The method aims to enhance the understanding of epithelial lung injury mechanisms and evaluate new therapies for acute respiratory distress syndrome.
Key Study Components
Area of Science
- Neuroscience
- Respiratory Medicine
- Pharmacology
Background
- Acute respiratory distress syndrome (ARDS) is a critical condition requiring novel therapeutic approaches.
- Halogenated agents like sevoflurane and isoflurane may have potential in treating lung injuries.
- Understanding the mechanisms of lung injury is essential for developing effective treatments.
- This study focuses on a method to control exposure to these agents in a laboratory setting.
Purpose of Study
- To develop a reliable protocol for studying lung injury and repair.
- To test halogenated adjuncts as potential therapies for ARDS.
- To improve the understanding of epithelial lung injury mechanisms.
Methods Used
- Construction of an airtight chamber using a hermetic polypropylene box.
- Drilling a hole for gas mixture input and sealing it with silicone.
- Cell culture techniques to expose cells to halogenated agents.
- Achieving controlled concentrations of sevoflurane or isoflurane.
Main Results
- The method allows for precise control over the concentration of halogenated agents.
- Facilitates the study of lung injury mechanisms in vitro.
- Provides a platform for testing novel therapies for ARDS.
- Demonstrates the simplicity and effectiveness of the protocol.
Conclusions
- The developed protocol is a valuable tool for lung injury research.
- It opens avenues for exploring new therapeutic options for ARDS.
- Further studies are needed to validate the findings and explore clinical applications.
Frequently Asked Questions
Executive Industry Relevance
This method enables precise in vitro control of halogenated gas concentrations to study epithelial lung injury mechanisms in ARDS. It provides a reproducible platform for evaluating novel therapeutics targeting alveolar injury and inflammation. The approach supports early-stage target validation and mechanistic de-risking in pulmonary drug discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses involving halogenated agents in lung injury pathways.
- Operational Value: Provides a standardized system for functional target validation of epithelial responses to anesthetic agents.
- Predictive Value: Supports predictive confidence by delivering quantifiable, time-resolved concentration data in culture medium.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream compound screening using controlled gas exposure.
- Reproducibility: Ensures consistent medium concentrations of sevoflurane and isoflurane, enabling reliable compound evaluation.
- Scalability: Uses a simple, airtight chamber design suitable for multi-well plate formats and repeated experiments.
Translational & Preclinical Research
- Disease Relevance: Models alveolar epithelial injury under physiologic conditions relevant to ARDS pathophysiology.
- Translational Continuity: Bridges in vitro findings to preclinical validation by defining exposure thresholds linked to biological effects.
- Risk-Adjusted Advancement: Informs go/no-go decisions by establishing concentration-effect relationships for safety and efficacy screening.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target engagement to lead optimization, particularly for pulmonary therapeutics targeting inflammatory and injurious pathways.
- Discovery Biology: Supports hypothesis testing of halogenated agents as modulators of epithelial injury and repair mechanisms.
- Screening: Enables assay standardization through stable, measurable gas concentrations in the liquid phase over time.
- Analytics: Generates quantitative dependent variable measurements (e.g., medium concentration mg/L) via gas mass spectrometry for condition comparison.
- Translational Research: Connects exposure dynamics to biological outcomes, supporting biomarker-aligned preclinical continuity.
- Enterprise Reuse: Offers a reusable, low-cost platform for iterative testing of anesthetic or gas-based therapeutics across projects.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in lung injury models by providing controlled, reproducible gas exposure conditions.
- Operational Value: Delivers standardization and reproducibility through sealed chamber design and real-time gas monitoring.
- Strategic Value: Improves capital efficiency by enabling early de-risking of halogenated adjuncts before costly in vivo studies.
- Portfolio Impact: Supports risk-adjusted prioritization of pulmonary drug candidates via defined exposure-response profiling.
Implementation Considerations
- Requires expertise in cell culture at air-liquid interface and gas handling systems.
- Needs access to anesthetic machine circuits, gas analyzers, and mass spectrometry for medium concentration validation.
- Demands cross-team standardization of exposure protocols, sealing techniques, and environmental controls (37°C, 5% CO2).
- Involves adaptation considerations for different cell types, plate formats, and halogenated agents beyond sevoflurane and isoflurane.
- Practical limitations include chamber volume constraints and equilibration time (~1 hour) to reach plateau concentrations in medium.
